Ding Jingxian, Guo Yonghong, Jiang Xiaoliu, Li Qingge, Li Kai, Liu Min, Fu Wenbing, Cao Yali
Department of Radiation Oncology, The Breast Cancer Institute, The Third Hospital of Nanchang, Nanchang, Jiangxi Province 330025, China.
Department of Radiation Oncology, The Fourth Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province 330003, China.
Onco Targets Ther. 2020 Oct 22;13:10749-10757. doi: 10.2147/OTT.S267984. eCollection 2020.
(SD) has been used in traditional Chinese medicine to treat pain, inflammation, and arthritis. Recently, it has been reported that SD extract may inhibit tumor growth, but the mechanism involved is elusive. The aim of this study was to investigate the anti-tumor activity of polysaccharides derived from SD in breast cancer and the underlying mechanisms.
Polysaccharides isolated from SD were analyzed using Fourier transform infrared (FT-IR) spectroscopy and gas chromatography-mass spectroscopy (GC-MS). Their effects on cell growth of U937, MCF-7, and MDA-MB-231, and tumor growth in a mouse MDA-MB 231 xenograft model were examined. Their role in U937 activation, MCF-7, and MDA-MB 231 cytokine release profiles were also tested.
In vitro studies showed that SD polysaccharides (SDPs) promoted U937 cell growth dose-dependently, with no obvious effect on growth of breast cancer cell lines MCF-7 and MDA-MB-231. SDP also showed an antagonistic effect against the growth inhibition of U937 by the culture supernatants of MCF-7 and MDA-MB-231, and reversed the polarization status of U937. Treatment of SCID mice bearing MDA-MB-231-derived xenograft tumors with SDP significantly reduced tumor growth. At all tested concentrations, no obvious toxic side-effects were recorded.
We tentatively concluded that SDPs potently promote the growth of U937 and activate it to inhibit the tumor growth of SCID mice bearing MDA-MB-231-derived xenograft tumors indirectly, with no obvious growth inhibition effects on MCF-7 and MDA-MB-231 in vitro. Our finding indicated that SDP could be a potential anticancer agent for breast cancer.
桑黄已被用于传统中药治疗疼痛、炎症和关节炎。最近,有报道称桑黄提取物可能抑制肿瘤生长,但其涉及的机制尚不清楚。本研究的目的是探讨桑黄多糖对乳腺癌的抗肿瘤活性及其潜在机制。
采用傅里叶变换红外光谱(FT-IR)和气相色谱-质谱联用(GC-MS)对从桑黄中分离得到的多糖进行分析。检测其对U937、MCF-7和MDA-MB-231细胞生长的影响,以及对小鼠MDA-MB 231异种移植模型肿瘤生长的影响。还测试了它们在U937激活、MCF-7和MDA-MB 231细胞因子释放谱中的作用。
体外研究表明,桑黄多糖(SDPs)剂量依赖性地促进U937细胞生长,对乳腺癌细胞系MCF-7和MDA-MB-231的生长无明显影响。SDP还对MCF-7和MDA-MB-231培养上清液对U937的生长抑制具有拮抗作用,并逆转了U937的极化状态。用SDP处理携带MDA-MB-231来源异种移植肿瘤的SCID小鼠,可显著降低肿瘤生长。在所有测试浓度下,均未记录到明显的毒副作用。
我们初步得出结论,SDPs可有效促进U937生长并激活其间接抑制携带MDA-MB-231来源异种移植肿瘤的SCID小鼠的肿瘤生长,在体外对MCF-7和MDA-MB-231无明显生长抑制作用。我们的发现表明,SDP可能是一种潜在的乳腺癌抗癌药物。